Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RemeGen CoFRA:REG +4.07%42 Graham Number is €0.52 as of Dec. 2025, which is 100% below its 10-year median of 11.44. GuruFocus rates FRA:REG with a GF Score™ of 42/100 and a GF Value™ of €21.87 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 252 Biotechnology companies, RemeGen Co ranks worse than 98.81% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-16), the stock price of RemeGen Co is €9.412. RemeGen Co's graham number for the quarter that ended in Dec. 2025 was €0.52. Therefore, RemeGen Co's Price to Graham Number ratio for today is 6.79.
The historical rank and industry rank for RemeGen Co's Graham Number or its related term are showing as below:
FRA:REG'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 6.73 Med: 11.44 Max: 19.11
Current: 13.84
During the past 8 years, the highest Price to Graham Number ratio of RemeGen Co was 19.11. The lowest was 6.73. And the median was 11.44.
FRA:REG's Price-to-Graham-Number is ranked worse than 98.81% of 252
companies
in the Biotechnology industry
Industry Median: 1.865
vs FRA:REG: 13.84
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
RemeGen Co (FRA:REG) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
RemeGen Co's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Dec. 2025 )
=
9.412
/
1.39
=
6.79
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
RemeGen Co Graham Number Related Terms
RemeGen Co Graham Number Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:REG vs VRTX, REGN, ALNY: Graham Number Comparison
For the Biotechnology subindustry, RemeGen Co's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Price-to-Graham-Number vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (FRA:REG) has a Graham Number of €0.52 as of Dec. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on RemeGen Co and its competitors. This is 95% below median its historical median of 11.44. Over the past decade, RemeGen Co's Graham Number has ranged from 6.73 to 19.11. According to the industry distribution chart, RemeGen Co ranks #249 out of 252 companies in the Biotechnology industry, placing it in the top 98.8%.
Is RemeGen Co's Graham Number too high?
RemeGen Co's current Graham Number of €0.52 is 95% below median its 10-year median of 11.44. Over the past 10 years, this metric has ranged from a low of 6.73 to a high of 19.11. Based on the distribution chart, RemeGen Co ranks #249 out of 252 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RemeGen Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Graham Number compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #249 out of 252 companies for Graham Number. This places RemeGen Co in the lower half of its industry. The industry median Graham Number is 1.87. Historically, RemeGen Co's own Graham Number has ranged from 6.73 to 19.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Biotechnology company?
The median Graham Number among Biotechnology companies is 1.87, based on 252 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Graham Number is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Graham Number is €0.52, which is 95% below median its own 10-year median of 11.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €21.87, compared to a current price of €9.41 — trading 57% below its estimated fair value. The current Graham Number is €0.52, which is 95% below median its 10-year median of 11.44. RemeGen Co's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Graham Number is €0.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.41 is trading 57% below its estimated GF Value™ of €21.87.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Graham Number: €0.52 (95% below median its 10-year median of 11.44)
GF Value™: €21.87 vs. price of €9.41 (57% below fair value)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
42GF Score
Get the complete analysis for FRA:REG
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
